The European Medicines Agency (EMA) announced, on Tuesday 12 October, that it is ending the rolling review of the Covid-19 CVnCoV vaccine developed by the pharmaceutical company CureVac.
“In its letter to EMA , the company stated that it withdrew because it decided to focus its efforts on a different Covid-19 vaccine development programme”, the EMA said, noting that CVnCoV had so far shown only modest efficacy (see EUROPE B12743A13).
The European Commission had concluded an advance...